Health Inequalities across North-West England
Novartis, a Life Science Company, specialise in research, development and commercialisation of new drug therapies medicines, with the aim to deliver them to as many people as possible.
As an expert in innovation development and integrated care systems, founder Prof Andrew Wardley said “I want innovation to be at the heart of our efforts to build healthcare systems back better and stronger. To achieve this, we need strong leadership from experienced clinical innovators. Clinical expertise is the point of truth that will enable the UK to unleash their vast scientific and technological potential.”
The proportion of people in England who survive their cancer diagnosis has been improving over time due to advances in early diagnosis and treatment. 50% of people diagnosed with cancer now survive their cancer for 10 years or more – double the percentage who survived 40 years ago. As a cancer survivor himself, Prof Andrew Wardley relates to the emotional, physical, and psychological challenges people experience when living with and beyond a life-threatening illness. Through first-hand experience, Prof Wardley relates to patient need for systemic anti-cancer therapy (SACT) drug treatment option, which increases roughly 10-15% per year, improving survival rates for cancer patients. An average of 28% of EU clinical trial applications have come from the UK (ABPI Clinical Trials Report 2019). This is only a fraction of the potential market opportunity open to the UK. As a National Oncology Centre, Cancer Services aim to increase efficiencies across time, reliability, governance and cost to deliver SACT treatments in the local communities.
Novartis, a Life Science Company, specialise in research, development and commercialisation of new drug therapies medicines, with the aim to deliver them to as many people as possible. Since 2014, Novartis Oncology has worked on many joint working projects across the UK. In a combined effort to improve treatment pathways and care for cancer patients, Novartis firmly believe that greater collaboration with Life Science Companies can support the NHS in meeting the healthcare challenges of the 21st century. However, billions more lack access to healthcare and medicines. Currently one-third of the world’s population does not have access to essential medicines and, with the global population projected to reach 9 billion by 2050, ensuring broad access is a critical issue.
Novartis has collaborated on joint working projects in Greater Manchester to use data analysis to evaluate the cancer pathway. The focus of these collaborations was to improve health outcomes by tackling the access barriers to cancer treatments across the UK. From his involvement in these projects, Professor Wardley saw the opportunity to use the findings of these projects to establish an independent not for profit, cross sector and multi-disciplinary Research Centre to address the challenges in equitable access and health inequalities
The healthcare system is the fundamental tool to provide access to all facets of healthcare, including asking and addressing the pertinent questions for all patients and ensuring they have access to relevant research opportunities. Healthcare systems must ensure affordability for patients, sustainability for all stakeholders and adaptability to respond to new diseases, changing demographics, scientific discoveries and dynamic technologies.
For more information about this collaboration or how to get involved please contact us at contactus@cancerservices.co.uk
